Summary
Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
History
Veru Inc. was founded in 1996 to provide innovative healthcare solutions focused on cancer care and assisted reproduction. Veru has since grown to become a leading provider of precision oncology products and comprehensive fertility services.
Mission
Veru is dedicated to revolutionizing cancer care, improving the lives of those affected by fertility challenges, and making drug development more efficient for the pharmaceutical industry.
Vision
Veru’s vision is to become the leader in innovative healthcare technologies, to achieve long-term sustainability, and to make a positive impact on the world.
Key Team
Dr. K. Gary Barnette Ph.D. (Chief Scientific Officer)
Mr. Samuel Fisch (Exec. Director of Investor Relations & Corp. Communications)
Mr. Michael J. Purvis (Exec. VP, Gen. Counsel & Corp. Strategy and Sec.)
Mr. Kevin J. Gilbert CPA, J.D. (Exec. VP of Corp. Devel.)
Dr. Domingo Rodriguez M.D. (Exec. VP of Global Clinical Operations)
Dr. Gary Bird Ph.D. (Exec. VP of Quality & Regulatory Affairs)
Mr. Joel Batten (Exec. VP & GM of Infectious Disease Franchise)
Recognition and Awards
Veru Inc. has received several awards in recognition of their commitment to advancing healthcare and innovation in cancer diagnostics and fertility. Most recently, Veru received the 2020 Technology Advancement Award from Frost & Sullivan for its innovative cancer diagnostics technology.
References
United States 